Insightful End Stage Renal Disease (ESRD) Drug Market Report 2025 – For Product, Marketing, and Strategy Teams

 This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the End Stage Renal Disease (ESRD) Drug industry.

 
 How has the end stage renal disease (esrd) drug market size changed in recent years, and what is the outlook ahead?
 The end stage renal disease (ESRD) drug market size has grown rapidly in recent years. It will grow from $131.41 billion in 2024 to $149.88 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increasing incidence of end stage renal disease, growing aging population, improved access to healthcare services, government initiatives and policies, increasing adoption of renal replacement therapies.
 
 The end stage renal disease (ESRD) drug market size is expected to see rapid growth in the next few years. It will grow to $268.44 billion in 2029 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to emerging therapies and drug innovations, increasing healthcare expenditure, rising global burden of chronic kidney diseases, personalized medicine approaches, regulatory support, and expedited approvals. Major trends in the forecast period include increasing incidence of end stage renal disease, advancements in treatment modalities, growing emphasis on precision medicine, development of combination therapies, technological integration in healthcare.
 
 Download Your Free Sample PDF:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
 
 What are the top economic and technological drivers pushing end stage renal disease (esrd) drug market growth?
 Rising cases of obesity and diabetes are expected to propel the growth of the end-stage renal disease (ESRD) drug market going forward. Obesity is described as abnormal or excessive fat buildup that poses a health concern. In contrast, diabetes is a chronic condition that happens when the pancreas does not create enough insulin or when the body cannot utilize the insulin produced efficiently. In patients with renal disease, managing fluid and electrolyte levels, blood pressure, and waste product elimination through dialysis can improve general health and well-being, which may lead to weight reduction and improve blood sugar control. For instance, in March 2022, according to World Obesity, a US-based membership organization representing national and regional associations dedicated to the study and management of obesity, the number of obese people is expected to rise to 892 million in 2025 and then to 1,025 million in 2030. Furthermore, in February 2023, according to the National Health Service, UK-based publicly funded healthcare system, It is estimated that by 2030, the number of people in the UK with diabetes could reach 5.5 million, impacting nearly 9% of the population. Therefore, the rising cases of obesity and diabetes will drive the market for end-stage renal disease (ESRD) drugs.
 
 How is the end stage renal disease (esrd) drug market segmented by product, application, and end-user?
 The end stage renal disease (ESRD) drug market covered in this report is segmented –
 
 1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
 2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
 
 Subsegments:
 1) By Calcimimetics: Cinacalcet, Etelcalcetide
 2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
 3) By Sterols: Ergocalciferol, Cholecalciferol
 4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
 5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
 6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
 
 View The Full Market Report:
 https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report
 
 Which trends are expected to dominate the end stage renal disease (esrd) drug market landscape in the coming years?
 Product innovations are a key trend in gaining popularity in the end-stage renal disease (ESRD) drug market. Major companies operating in the end-stage renal disease (ESRD) drug market are focused on developing innovative solutions to sustain in the market. For instance, in April 2022, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology firm, announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the possible treatment of patients with chronic kidney disease anemia (CKD). The new product is based on the unique Nobel prize-winning science that proved how cells sense and adapt to oxygen availability.
 
 Which leading companies are dominating the end stage renal disease (esrd) drug market landscape?
 Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
 
 Which geographic areas are expected to offer the highest growth opportunities in theend stage renal disease (esrd) drug market?
 North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 How Can Companies Use The End Stage Renal Disease (ESRD) Drug Market Report to Drive Business Results?
 This report provides actionable insights tailored for business use — not academic analysis. Companies can leverage the data to:
 • Time market entry or expansion using growth forecasts and CAGR trends.
 • Develop competitive products by tracking key technology shifts and user preferences.
 • Tailor regional strategies with in-depth geographic data and local market dynamics.
 • Benchmark and plan partnerships using competitive landscape insights.
 
 Purchase The Report And Get A Swift Delivery:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437
 
 Need Customized Data On End Stage Renal Disease (ESRD) Drug Market?
 For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
 
 Request Customized Data:
 https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company